Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Net Income (2016 - 2024)

Seres Therapeutics' Net Income history spans 10 years, with the latest figure at $139.8 million for Q3 2024.

  • For Q3 2024, Net Income rose 2144.32% year-over-year to $139.8 million; the TTM value through Jun 2025 reached $139.8 million, up 196.15%, while the annual FY2024 figure was $125.9 million, 64.79% up from the prior year.
  • Net Income for Q3 2024 was $139.8 million at Seres Therapeutics, up from -$6.7 million in the prior quarter.
  • Across five years, Net Income topped out at $139.8 million in Q3 2024 and bottomed at -$124.7 million in Q4 2023.
  • The 5-year median for Net Income is -$21.2 million (2020), against an average of -$19.3 million.
  • The largest annual shift saw Net Income crashed 5574.51% in 2023 before it soared 2144.32% in 2024.
  • A 5-year view of Net Income shows it stood at -$18.0 million in 2020, then tumbled by 175.35% to -$49.7 million in 2021, then surged by 95.58% to -$2.2 million in 2022, then plummeted by 5574.51% to -$124.7 million in 2023, then skyrocketed by 212.15% to $139.8 million in 2024.
  • Per Business Quant, the three most recent readings for MCRB's Net Income are $139.8 million (Q3 2024), -$6.7 million (Q2 2024), and -$7.2 million (Q1 2024).